Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $11.84 in the prior trading day, Caredx Inc (NASDAQ: CDNA) closed at $11.85, up 0.08%. In other words, the price has increased by $0.08 from its previous closing price. On the day, 0.94 million shares were traded. CDNA stock price reached its highest trading level at $12.08 during the session, while it also had its lowest trading level at $11.75.
Ratios:
Our goal is to gain a better understanding of CDNA by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.39 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 53.09. For the most recent quarter (mrq), Quick Ratio is recorded 3.00 and its Current Ratio is at 3.30. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on January 15, 2025, Upgraded its rating to Equal Weight and sets its target price to $24 from $28 previously.
On August 28, 2024, Wells Fargo started tracking the stock assigning a Underweight rating and target price of $28.
BTIG Research Upgraded its Neutral to Buy on August 19, 2024, while the target price for the stock was maintained at $40.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 05 ’25 when Novack Jeffrey Adam sold 2,688 shares for $12.79 per share. The transaction valued at 34,381 led to the insider holds 112,930 shares of the business.
Jeffrey Adam Novack bought 2,688 shares of CDNA for $33,869 on Aug 05 ’25. On Jul 07 ’25, another insider, Maag Peter, who serves as the Director of the company, sold 10,000 shares for $18.58 each. As a result, the insider received 185,831 and left with 308,846 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDNA now has a Market Capitalization of 630738816 and an Enterprise Value of 473606336. As of this moment, Caredx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.61. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.85 while its Price-to-Book (P/B) ratio in mrq is 1.93. Its current Enterprise Value per Revenue stands at 1.39 whereas that against EBITDA is -16.622.
Stock Price History:
The Beta on a monthly basis for CDNA is 2.27, which has changed by -0.63482285 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, CDNA has reached a high of $34.84, while it has fallen to a 52-week low of $10.96. The 50-Day Moving Average of the stock is -26.71%, while the 200-Day Moving Average is calculated to be -39.28%.
Shares Statistics:
The stock has traded on average 1.51M shares per day over the past 3-months and 1474270 shares per day over the last 10 days, according to various share statistics. A total of 53.22M shares are outstanding, with a floating share count of 49.66M. Insiders hold about 6.71% of the company’s shares, while institutions hold 104.64% stake in the company. Shares short for CDNA as of 1753920000 were 6181022 with a Short Ratio of 4.10, compared to 1751241600 on 6396705. Therefore, it implies a Short% of Shares Outstanding of 6181022 and a Short% of Float of 11.89.
Earnings Estimates
The market rating of Caredx Inc (CDNA) is currently shaped by the ongoing analysis conducted by 5.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.2, with high estimates of $0.23 and low estimates of $0.17.
Analysts are recommending an EPS of between $0.57 and $0.48 for the fiscal current year, implying an average EPS of $0.54. EPS for the following year is $0.9, with 5.0 analysts recommending between $1.11 and $0.73.
Revenue Estimates
7 analysts predict $95.4M in revenue for the current quarter. It ranges from a high estimate of $96.52M to a low estimate of $93.7M. As of the current estimate, Caredx Inc’s year-ago sales were $82.88MFor the next quarter, 7 analysts are estimating revenue of $102.42M. There is a high estimate of $103.9M for the next quarter, whereas the lowest estimate is $101.5M.
A total of 7 analysts have provided revenue estimates for CDNA’s current fiscal year. The highest revenue estimate was $370.9M, while the lowest revenue estimate was $367.2M, resulting in an average revenue estimate of $369.2M. In the same quarter a year ago, actual revenue was $333.79MBased on 7 analysts’ estimates, the company’s revenue will be $417.73M in the next fiscal year. The high estimate is $430.37M and the low estimate is $394.4M.
